Data from Pharmawand - Curated by EPG Health - Date added 13 March 2019

Almirall, S.A. announced that NICE (National Institute for Health and Care Excellence) has provisionally recommended approval of Ilumetri (tildrakizumab) (Ilumya in the US), a humanized, high-affinity IL-23p19 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Following a single health technology assessment submission to NICE in August 2018 and the subsequent questions for clarification and appraisal committee meetings, NICE completed their assessment of tildrakizumab and has now issued a Final Appraisal Determination (FAD) provisionally recommending tildrakizumab as a cost effective treatment option for the NHS for the patients specified in the FAD. Final NICE approval is expected in April 2019.

Learn more about psoriasis in our Psoriasis Learning Zone.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.



See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Load more

Related Content